Icon
+91 94997 68112
Login Register

Kalydeco - (150 mg; Tablet, Oral)

Ivacaftor Vertex pharma
150 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
KALYDECO is indicated for the treatment CF in pediatric patients age 2-17 years of age who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation
Yes
*** ****** ** ***. *** ****** ***** * **** ** ** ****** '*** *** *** *********. ** ****** **** **** *** ****** ****** ** *** ****. ********* ** ****** ****** *** ******, ******** ****** ** ******** ****** ** ******. **, **** ** *** ******* *** ****** ******* ****** ******. ***** ** **** **, **** ****** **** ***** ** ****** ** '***.
Kalydeco Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9
*** ****** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* ******* *******
***** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* ******* *******
********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** ****** *** \ ********* *** **, **** ******* **** ******* *** **** (******** ******) *** *** ****
***** **\ ** *** **, **** ******* ********* ******** ******* *** **** (******** ******) *** *** ****
********* ** \ ** *** **, **** ******* **** ******* *** **** (******** ******) *** *** ****
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : *** ****** ******** ****** ****** ***** **'* **** ** ************* ** ****** '***.
  3. *** **, **** : ****** ****** ***** * **** ******* *** ****** ** ****** '***.
  4. *** *, **** : ***** ******** ****** ** ***** ****-** ******.
  5. *** **, **** : ****** ****** ***** * **** ******* ***** ** ****** '***.
  6. *** **, **** : ********* ******** ****** ** ***** ****-** ******.
  7. *** *, **** : ****** **** ********* **** ************ ** ****** '***.
  8. *** **, **** : ****** ****** **** ***** *** ********* **** ***** ****** ****** '***.
  9. *** **, **** : ****** ****** **** *** ****** **** ***** ****** ****** '***.
  10. : ****** ****** *** ***** ******* ********** **** ******* *****.
  11. *** **, **** : ****** ****** *** ***** ******* ********** **** ******* *****.
  12. *** *, **** : ****** ****** *** ********* ******* ********** **** ******* *****.
  13. *** *, **** : ****** *** *** ****** ******* ********** **** ************ ** ****** '*** *** '***.

Kalydeco - (25, 50, 75 mg/packet ; Oral Granules)

Ivacaftor Vertex pharma
25, 50, 75 mg/packet ; Oral Granules
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
None None
KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R and R117H.
Yes
********* ** ****** ****** *** ******, ******** ****** ** ******** ****** ** ******. **, **** ** *** ******* *** ****** ******* ****** ******.
Kalydeco Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13
***** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** (***** ******)
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ ********* *** **, **** ******* **** ***** *** **** (******** ******)
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : ***** ******** ****** ***** *** ****-** ****** **** ******* '***, '***, *** '***
  3. *** **, **** : ****** **** ***** **** ************ ** ******* '***, '***, '***, *** '***.
  4. *** **, **** : ****** **** ***** **** ***** ****** ****** '***.
  5. *** **, **** : ***** ******** ****** ***** *** **** ** ****** **** ***** ****** ****** ** '***.
  6. *** **, **** : ****** **** ***** **** ************ ** ***** ****** ****** ** '***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.